STAT

STAT+: Pharmalittle: We’re watching a Cytokinetics deal with Royalty Pharma, Cue Health shutting down, and more

Source: Alex Hogan/STAT

Top of the morning to you. I’m filling in for Ed Silverman this morning, which means you’re getting Brooklyn instead of the Pharmalot compound, Barry’s the . I know, we are all eagerly awaiting the return of our beloved Pharmalot, but let’s get to it.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An ‘Unaffordable’ Novartis Drug, A Proposed Patent Rule, And More
In today's Pharmalittle roundup, we're reading about an "unaffordable" Novartis drug, a new patent office rule, and more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An FDA Meeting On MDMA, A New Obesity Pill, And More
Structure Therapeutics disclosed that its oral obesity drug helped reduce weight by 6.2% on average in a mid-stage study, exceeding Wall Street expectations.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Merck Deal, Weight Loss Drugs, And Lots More
Merck has struck a $1.3 billion deal to buy Eyebiotech, a move that would push the big drugmaker into the large and growing market for eye care.

Related Books & Audiobooks